Core Viewpoint - Celularity Inc. reported significant growth in net revenues for the year ending December 31, 2024, totaling $54.2 million, which represents an increase of $31.4 million or 138.1% compared to the previous year, driven primarily by strong sales in wound care applications [1][3]. Financial Performance - Net revenues for 2024 were $54.2 million, an increase of $31.4 million or 138.1% from the prior year, with product sales in wound care applications rising by $22.2 million, reflecting a growth of 168.7% [1][3]. - Total operating expenses decreased to $92.6 million, down by $122.5 million or 57.0% compared to 2023, mainly due to the absence of goodwill and in-process research and development impairments [4][6]. - Loss from operations for 2024 was $38.4 million, a decrease of $153.9 million or 80.1% from the previous year, attributed to higher revenues and lower operating expenses, which improved gross margin [4][6]. Product and Market Development - The company experienced strong sales growth in its Biovance® product line, which is expected to continue contributing positively to revenue in the upcoming quarters [2]. - Celularity received recommendation letters from the U.S. FDA Tissue Reference Group for new additions to its portfolio of human placental-derived advanced biomaterial products, indicating a commitment to innovation in the wound care sector [2]. Balance Sheet Overview - As of December 31, 2024, total assets were $132.7 million, a decrease from $143.9 million in 2023, with current assets amounting to $20.6 million [8][9]. - Total liabilities increased to $123.8 million from $102.9 million in the previous year, with current liabilities at $53.7 million [8][9]. Company Background - Celularity Inc. is focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies, aiming to address significant unmet global needs for effective and affordable therapies [10].

- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gen ...

A Commercial-Stage Bioelectronic Medicine & Wellness Company Nasdaq: ECOR Corporate Presentation May 2025 Forward Looking Statement In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital resources, strategy and growth reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to a number o ...

CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net r ...

Prof. Mike Chan unveils the Human Cytology Atlas, mapping 400+ human cell types and setting a new standard in regenerative medicine — proving that true healing is precise and personal. https://european-wellness.eu/ HEIDELBERG, Germany , May 08, 2025 (GLOBE NEWSWIRE) -- A landmark scientific breakthrough has mapped over 400 human cell types — offering powerful confirmation for the precision medicine philosophy Prof. Mike Chan has championed for decades: that real regenerative medicine demands matchin ...

在全球经济格局深刻调整的当下，"东升西落"不再仅是中国内部的战略共识，而是逐渐成为全球资本市 场的现实写照。美国对中国发起的关税战不仅未能遏制中国的发展，反而在全球范围内引发了对美国经 济政策的不信任。与此同时，美债收益率的飙升和美股高估值的持续，使得美元资产的信用风险日益凸 显。在这样的背景下，中国以其稳健的经济增长和日益完善的投资环境，成为全球资本寻求避风港的新 选择。外资LP们开始悄然布局中国市场，寻找新的增长点和投资机会。这一趋势不仅体现了全球资本 对中国市场的重新评估，也标志着中国在全球资本流动中的角色正在发生深刻变化。 外资重新"认识"中国 今年4月以来美国对全球，尤其是中国，发起的关税战引发了广泛的国际抵制。曾被视为"避风港"的美 元资产，如今正面临信任危机。美债收益率飙升、美股高估值泡沫、以及对华关税战的持续升级，使得 投资者开始重新审视美国资产的安全性。与此同时，中国市场以其稳定的政策环境和科技创新能力，逐 渐成为全球资本的避风港。 美国国债市场一直被视为全球最安全的投资标的。然而，美国联邦债务总额激增至36.2万亿美元，其中 约9.2万亿美元将在2025年到期，占GDP的近31% 。这一庞 ...

科技创新是高质量发展的核心驱动力。自《粤港澳大湾区发展规划纲要》发布以来，大湾区科技创新建 设按下"加速键"，香港、澳门与粤港澳大湾区内地城市珠联璧合，深化产学研协同创新，汇聚全球创新 资源，不断刷新科技创新的"成绩单"。 港澳科创事业的飞速发展，离不开中央的大力支持。国家"十四五"规划纲要明确提出支持香港建设国际 创新科技中心，多项中央惠港惠澳科技政策相继落地，为香港、澳门的科创发展提供坚实依托和强大底 气。从中央财政科研经费过境支持港澳科技发展，到多个国家级科学基金项目向港澳地区开放；从港澳 载荷专家首次入选国家预备航天员，到香港大学、澳门科技大学获得研究嫦娥月壤的宝贵机会……在发 展科技创新的道路上，中央一直是港澳最强大的后盾和支撑。而这也为港澳产业转型升级、拓展发展新 空间、保持长期繁荣稳定，注入了强劲动力。 走进香港数码港，浓厚的创新气息扑面而来。人工智能、区块链、金融科技……新兴产业初创公司不断 涌现、快速成长，尽显香港科创发展的澎湃活力。 澳门科创，同样好风正起。在中药质量研究、太空科学、健康科学等领域，澳门发展势头正好，高水平 科研成果不断涌现，"科创"成为澳门的崭新名片。 面对科技创新带来的 ...

enGene Holdings (ENGN) 2025 Conference May 05, 2025 02:00 PM ET Speaker0 For our next presentation, it's from NGIN, and we have the pleasure of having Ron Cooper, the CEO, here to present for us. So take it away, Ron. Thank you. Speaker1 Well, good afternoon, everybody. It's a real pleasure to be here. You know, first of all, thanks to the conference organizers. It's great to be back in back in Canada. NGEN is a company form formed in Canada. Our headquarters is in Montreal. Our labs are there, and we have ...

Core Insights - Lexeo Therapeutics, Inc. is presenting new data on its AAV manufacturing approach at the upcoming ASGCT meeting, highlighting advancements in production efficiency and quality [1][2] - The company has optimized a manufacturing platform that enhances scalability, reduces costs, and maintains the purity and potency of AAV products, which is crucial for its clinical-stage gene therapy programs [2] Company Overview - Lexeo Therapeutics is a clinical stage genetic medicine company based in New York City, focused on innovative treatments for cardiovascular diseases [3] - The company is developing therapeutic candidates targeting genetic causes of conditions such as Friedreich ataxia cardiomyopathy and plakophilin-2 arrhythmogenic cardiomyopathy, addressing significant unmet medical needs [3] Presentation Details - Lexeo will present two key abstracts at the ASGCT meeting: - "Improving VP1 Ratios Impact on CQAs in rh10 AAV Manufactured through Sf9 Platform" on May 13, 2025 [2] - "Development of a Novel High-Yielding Scalable Sf9-Baculovirus Platform to Produce Quality AAV at 200L Scale" on May 15, 2025 [2]

转自：新华财经 "穿越"皇家养生圣地 沉浸式体验灵芝文化 本届寿仙谷灵芝文化节巧妙融合了传统中医药文化与现代互动体验，通过"中医文化展示+宋韵游园+趣味打卡"创新形式，让参与者在移步换景间感受灵芝 文化的深厚底蕴。 在慈福宫前的中医药创意文化市集上，灵芝宋韵四雅成为亮点，不仅能喝到新晋网红饮品灵芝咖啡，吃到美味的药膳美食，还能玩到各种别具特色的传统娱 乐项目……同时，还有DIY香囊、定制如意手串等精彩国潮文创，吸引了不少网红达人打卡互动。 "宋韵雅宴"以《仙草降世》《白蛇情劫》《神农百草·以身试药》等艺术表演，再现了灵芝在传统文化中的传奇色彩。以灵芝入馔创新宋宴，诠释"古方今 饪"的跨界魅力，"曲水流觞飞花令"则让嘉宾在诗词歌赋中感受灵芝文化的深厚底蕴。 "白娘子"现场分享 "健康天团"共话灵芝文化 以"德寿"为名，以灵芝为脉。活动现场，与寿仙谷结缘的六位"跨界嘉宾"，共话古今，开启了一场温情沙龙。 4月30日，第五届中国·寿仙谷灵芝文化节在杭州南宋德寿宫启幕。本届灵芝文化节以文化市集、启幕盛典、宋韵雅宴三大篇章展开，来自中医药、科研、体 育、电商等各界嘉宾齐聚一堂，展现了灵芝产业"承古法、立新章"的蓬勃气象 ...